<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34266783</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9177</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nephrologie &amp; therapeutique</Title><ISOAbbreviation>Nephrol Ther</ISOAbbreviation></Journal><ArticleTitle>[Kidney damage in COVID-19].</ArticleTitle><Pagination><StartPage>203</StartPage><EndPage>207</EndPage><MedlinePgn>203-207</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nephro.2021.06.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1769-7255(21)00138-3</ELocationID><Abstract><AbstractText>COVID-19 is a disease caused by the RNA virus SARS-CoV-2. It is characterised by an attack mainly affecting the respiratory system. There is renal involvement which is characterised by three main types of damage, acute tubular necrosis occurring in the most severe cases, proximal tubulopathy which is a prognostic marker of the disease and segmental and focal hyalinosis occurring in a genetically predisposed terrain. The pathophysiology of SARS-CoV-2 renal involvement is not yet defined. The direct role of the virus is debated, whereas the cytokine storm and the hypoxic and thrombotic complications seem more important. The long-term outcome of the renal damage appears to be quite good. Long-term follow-up will allow us to say whether the renal damage is part of the long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Soci&#xe9;t&#xe9; francophone de n&#xe9;phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burtey</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Aix Marseille Univ, Inserm, INRAE, C2VN, 13005 Marseille, France; Aix-Marseille Univ, Centre de n&#xe9;phrologie et transplantation r&#xe9;nale, H&#xf4;pital de la Conception, 147, boulevard Baille, 13005 Marseille, France. Electronic address: Stephane.burtey@univ-amu.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sall&#xe9;e</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Aix Marseille Univ, Inserm, INRAE, C2VN, 13005 Marseille, France; Aix-Marseille Univ, Centre de n&#xe9;phrologie et transplantation r&#xe9;nale, H&#xf4;pital de la Conception, 147, boulevard Baille, 13005 Marseille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Les atteintes r&#xe9;nales de la COVID-19.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Nephrol Ther</MedlineTA><NlmUniqueID>101248950</NlmUniqueID><ISSNLinking>1769-7255</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005923" MajorTopicYN="N">Glomerulosclerosis, Focal Segmental</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007683" MajorTopicYN="N">Kidney Tubular Necrosis, Acute</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText>La COVID-19&#xa0;est une affection due &#xe0; un virus &#xe0; ARN, le SARS-CoV-2. Elle se caract&#xe9;rise par une atteinte touchant essentiellement l&#x2019;appareil respiratoire. Il existe une atteinte r&#xe9;nale qui se caract&#xe9;rise par trois atteintes principales : une n&#xe9;crose tubulaire aigu&#xeb; survenant dans les cas les plus s&#xe9;v&#xe8;res, une tubulopathie proximale, qui est un marqueur pronostique de la maladie, et une hyalinose segmentaire et focale survenant sur un terrain g&#xe9;n&#xe9;tiquement pr&#xe9;dispos&#xe9;. La physiopathologie de l&#x2019;atteinte r&#xe9;nale du SARS-CoV-2&#xa0;n&#x2019;est pas encore d&#xe9;finie. Le r&#xf4;le direct du virus est discut&#xe9; alors que la temp&#xea;te cytokinique et les complications hypoxiques et thrombotiques semblent plus importantes. Le devenir &#xe0; long terme des atteintes r&#xe9;nales para&#xee;t plut&#xf4;t bon. Un suivi au long cours permettra de dire si l&#x2019;atteinte r&#xe9;nale fait partie du COVID long.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Soci&#xe9;t&#xe9; francophone de n&#xe9;phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute tubular necrosis</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Focal segmental glomerulosclerosis</Keyword><Keyword MajorTopicYN="N">Hyalinose segmentaire et focale</Keyword><Keyword MajorTopicYN="N">N&#xe9;crose tubulaire aigu&#xeb;</Keyword><Keyword MajorTopicYN="N">Proximal tubulopathy</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Tubulopathie proximale</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>16</Day><Hour>5</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34266783</ArticleId><ArticleId IdType="pmc">PMC8221000</ArticleId><ArticleId IdType="doi">10.1016/j.nephro.2021.06.002</ArticleId><ArticleId IdType="pii">S1769-7255(21)00138-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19&#xa0;Map. Johns Hopkins Coronavirus Resource Centre n.d. (acc&#xe8;s au site web : 31 mai 2021) : https://coronavirus.jhu.edu/map.html.</Citation></Reference><Reference><Citation>Greenhalgh T., Jimenez J.L., Prather K.A., Tufekci Z., Fisman D., Schooley R. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. Lancet Lond Engl. 2021;397:1603&#x2013;1605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049599</ArticleId><ArticleId IdType="pubmed">33865497</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdanpanah F., Garg A., Shadman S., Asmarz H.Y. Literature review of COVID-19, pulmonary and extrapulmonary disease. Am J Med Sci. 2021;361:567&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7859706</ArticleId><ArticleId IdType="pubmed">33785204</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith K.D., Akilesh S. Pathogenesis of coronavirus disease 2019-associated kidney injury. Curr Opin Nephrol Hypertens. 2021;30:324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">33767060</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicosia R.F., Ligresti G., Caporarello N., Akilesh S., Ribatti D. COVID-19&#xa0;vasculopathy: mounting evidence for an indirect mechanism of endothelial injury. Am J Pathol. 2021 doi: 10.1016/j.ajpath.2021.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2021.05.007</ArticleId><ArticleId IdType="pmc">PMC8141344</ArticleId><ArticleId IdType="pubmed">34033751</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau W.L., Zuckerman J.E., Gupta A., Kalantar-Zadeh K. The COVID-kidney controversy: can SARS-CoV-2&#xa0;cause direct renal infection? Nephron. 2021;145:275&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018211</ArticleId><ArticleId IdType="pubmed">33601392</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheblawi M., Wang K., Viveiros A., Nguyen Q., Zhong J.C., Turner A.J., et al. Angiotensin-converting enzyme 2: SARS-CoV-2&#xa0;receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126:1456&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188049</ArticleId><ArticleId IdType="pubmed">32264791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lely A.T., Hamming I., van Goor H., Navis G.J. Renal ACE2&#xa0;expression in human kidney disease. J Pathol. 2004;204:587&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">15538735</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., von Brunn A., Zhu D. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. Med Drug Discov. 2020;7:100056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364167</ArticleId><ArticleId IdType="pubmed">32835213</ArticleId></ArticleIdList></Reference><Reference><Citation>Allam L., Ghrifi F., Mohammed H., El Hafidi N., El Jaoudi R., El Harti J., et al. Targeting the GRP78-dependant SARS-CoV-2&#xa0;cell entry by peptides and small molecules. Bioinforma Biol Insights. 2020;14 1177932220965505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7585878</ArticleId><ArticleId IdType="pubmed">33149560</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Zhang Y., Zeng X., Chen H., Chen Y., Yang D., et al. Kidney injury molecule-1&#xa0;is a potential receptor for SARS-CoV-2. J Mol Cell Biol. 2021 doi: 10.1093/jmcb/mjab003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjab003</ArticleId><ArticleId IdType="pmc">PMC7928767</ArticleId><ArticleId IdType="pubmed">33493263</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung M.L., Teng J.L.L., Jia L., Zhang C., Huang C., Cai J.P., et al. Soluble ACE2-mediated cell entry of SARS-CoV-2&#xa0;via interaction with proteins related to the renin-angiotensin system. Cell. 2021;184 2212-2228.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7923941</ArticleId><ArticleId IdType="pubmed">33713620</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemieniuk R.A., Bartoszko J.J., Ge L., Zeraatkar D., Izcovich A., Kum E., et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020:370. doi: 10.1136/bmj.m2980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2980</ArticleId><ArticleId IdType="pmc">PMC7390912</ArticleId><ArticleId IdType="pubmed">32732190</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj V., Khan M.S., Bavishi C., Dapaah-Afriyie K., Finn A., Lal A., et al. Tocilizumab in hospitalized patients with COVID-19: A meta analysis of randomized controlled trials. Lung. 2021 doi: 10.1007/s00408-021-00451-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-021-00451-9</ArticleId><ArticleId IdType="pmc">PMC8164079</ArticleId><ArticleId IdType="pubmed">34050796</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J.Y., Wang B., Lv L.L., Liu B.C. Pathogenesis of acute kidney injury in coronavirus disease 2019. Front Physiol. 2021;12:586589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928360</ArticleId><ArticleId IdType="pubmed">33679428</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Stang M.B., Desenclos J., Flamant M., Chousterman B.G., Tabibzadeh N. The good treatment, the bad virus, and the ugly inflammation: Pathophysiology of kidney involvement during COVID-19. Front Physiol. 2021:12. doi: 10.3389/fphys.2021.613019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2021.613019</ArticleId><ArticleId IdType="pmc">PMC7993058</ArticleId><ArticleId IdType="pubmed">33776785</ArticleId></ArticleIdList></Reference><Reference><Citation>McAdams M., Ostrosky-Frid M., Rajora N., Hedayati S. Effect of COVID-19&#xa0;on kidney disease incidence and management. Kidney. 2021;2:141&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8785734</ArticleId><ArticleId IdType="pubmed">35368812</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.F., Zhang Z., Pan X.L., Xing G.L., Zhang Y., Liu Z.S., et al. The chronic kidney disease and acute kidney injury involvement in COVID-19&#xa0;pandemic: A systematic review and meta-analysis. PLOS One. 2021;16 e0244779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785235</ArticleId><ArticleId IdType="pubmed">33400721</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver S.A., Beaubien-Souligny W., Shah P.S., Harel S., Blum D., Kishibe T., et al. The prevalence of acute kidney injury in patients hospitalized with COVID-19&#xa0;infection: a systematic review and meta-analysis. Kidney Med. 2021;3 83-98.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723763</ArticleId><ArticleId IdType="pubmed">33319190</ArticleId></ArticleIdList></Reference><Reference><Citation>Charytan D.M., Parnia S., Khatri M., Petrilli C.M., Jones S., Benstein J., et al. Decreasing incidence of acute kidney injury in patients with COVID-19&#xa0;critical illness in New York city. Kidney Int Rep. 2021;6:916&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857986</ArticleId><ArticleId IdType="pubmed">33558853</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens J.S., King K.L., Robbins-Juarez S.Y., Khairallah P., Toma K., Verduzco H.A., et al. High rate of renal recovery in survivors of COVID-19&#xa0;associated acute renal failure requiring renal replacement therapy. PLOS One. 2020;15 e0244131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7769434</ArticleId><ArticleId IdType="pubmed">33370368</ArticleId></ArticleIdList></Reference><Reference><Citation>Hultstr&#xf6;m M., Lipcsey M., Wallin E., Larsson I.-M., Larsson A., Frithiof R., et al. Severe acute kidney injury associated with progression of chronic kidney disease after critical COVID-19. Crit Care Lond Engl. 2021;25:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7829656</ArticleId><ArticleId IdType="pubmed">33494766</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent J., Aklilu A., Yamamoto Y., Simonov M., Li F., Biswas A., et al. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. JAMA Netw Open. 2021;4 e211095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7948062</ArticleId><ArticleId IdType="pubmed">33688965</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., et al. Post-acute COVID-19&#xa0;syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Teoh J.Y.C., Yip T.C.F., Lui G.C.Y., Wong V.W.S., Chow V.C.Y., Ho T.H.Y., et al. Risks of AKI and major adverse clinical outcomes in patients with severe acute respiratory syndrome or coronavirus disease 2019. J Am Soc Nephrol. 2021;32:961&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8017544</ArticleId><ArticleId IdType="pubmed">33483314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kormann R., Jacquot A., Alla A., Corbel A., Koszutski M., Voirin P., et al. Coronavirus disease 2019: acute Fanconi syndrome precedes acute kidney injury. Clin Kidney J. 2020;13:362&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314200</ArticleId><ArticleId IdType="pubmed">32695327</ArticleId></ArticleIdList></Reference><Reference><Citation>Huart J., Bouquegneau A., Lutteri L., Erpicum P., Grosch S., R&#xe9;simont G., et al. Proteinuria in COVID-19: prevalence, characterization and prognostic role. J Nephrol. 2021;34:355&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7823174</ArticleId><ArticleId IdType="pubmed">33484426</ArticleId></ArticleIdList></Reference><Reference><Citation>Werion A., Belkhir L., Perrot M., Schmit G., Aydin S., Chen Z., et al. SARS-CoV-2&#xa0;causes a specific dysfunction of the kidney proximal tubule. Kidney Int. 2020;98:1296&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7416689</ArticleId><ArticleId IdType="pubmed">32791255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouahmi H., Courjon J., Morand L., Fran&#xe7;ois J., Bruckert V., Lombardi R., et al. Proteinuria as a biomarker for COVID-19&#xa0;severity. Front Physiol. 2021;12:611772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7985082</ArticleId><ArticleId IdType="pubmed">33767630</ArticleId></ArticleIdList></Reference><Reference><Citation>Karras A., Livrozet M., Lazareth H., Benichou N., Hulot J.S., Fayol A., et al. Proteinuria and clinical outcomes in hospitalized COVID-19&#xa0;patients: a retrospective single-center study. Clin J Am Soc Nephrol CJASN. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092053</ArticleId><ArticleId IdType="pubmed">33661756</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty A.A., Tawhari I., Safar-Boueri L., Seif N., Alahmadi A., Gargiulo R., et al. COVID-19-associated glomerular disease. J Am Soc Nephrol. 2021;32:33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894674</ArticleId><ArticleId IdType="pubmed">33214201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Larsen C.P., Hernandez-Arroyo C.F., Mohamed M.M.B., Caza T., Sharshir M., et al. AKI and collapsing glomerulopathy associated with COVID-19&#xa0;and APOL1&#xa0;high-risk genotype. J Am Soc Nephrol. 2020;31:1688&#x2013;1695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460910</ArticleId><ArticleId IdType="pubmed">32561682</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman D.J., Pollak M.R. APOL1&#xa0;nephropathy: From genetics to clinical applications. Clin J Am Soc Nephrol. 2021;16:294&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7863644</ArticleId><ArticleId IdType="pubmed">32616495</ArticleId></ArticleIdList></Reference><Reference><Citation>Meliambro K., Li X., Salem F., Yi Z., Sun Z., Chan L., et al. Molecular analysis of the kidney from a patient with COVID-19-associated collapsing glomerulopathy. Kidney Med. 2021 doi: 10.1016/j.xkme.2021.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xkme.2021.02.012</ArticleId><ArticleId IdType="pmc">PMC8080498</ArticleId><ArticleId IdType="pubmed">33942030</ArticleId></ArticleIdList></Reference><Reference><Citation>Caramaschi S., Kapp M.E., Miller S.E., Eisenberg R., Johnson J., Epperly G., et al. Histopathological findings and clinicopathologic correlation in COVID-19: a systematic review. Mod Pathol. 2021 doi: 10.1038/s41379-021-00814-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41379-021-00814-w</ArticleId><ArticleId IdType="pmc">PMC8141548</ArticleId><ArticleId IdType="pubmed">34031537</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock H.A., Goldsmith C.S., Miller S.E. Best practices for correctly identifying coronavirus by transmission electron microscopy. Kidney Int. 2021;99:824&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7825881</ArticleId><ArticleId IdType="pubmed">33493525</ArticleId></ArticleIdList></Reference><Reference><Citation>Guervilly C., Burtey S., Sabatier F., Cauchois R., Lano G., Abdili E., et al. Circulating endothelial cells as a marker of endothelial injury in severe COVID -19. J Infect Dis. 2020;222:1789&#x2013;1793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454721</ArticleId><ArticleId IdType="pubmed">32812049</ArticleId></ArticleIdList></Reference><Reference><Citation>Guervilly C., Bonifay A., Burtey S., Sabatier F., Cauchois R., Abdili E., et al. Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19. Blood Adv. 2021;5:628&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846479</ArticleId><ArticleId IdType="pubmed">33560376</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouquegneau A., Erpicum P., Grosch S., Habran L., Hougrand O., Huart J., et al. COVID-19-associated nephropathy includes tubular necrosis and capillary congestion, with evidence of SARS-CoV-2&#xa0;in the nephron. Kidney. 2021 doi: 10.34067/KID.0006992020.</Citation><ArticleIdList><ArticleId IdType="doi">10.34067/KID.0006992020</ArticleId><ArticleId IdType="pmc">PMC8791309</ArticleId><ArticleId IdType="pubmed">35373054</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlicot S., Jamme M., Gaillard F., Oniszczuk J., Couturier A., May O., et al. The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria. Nephrol Dial Transplant. 2021 doi: 10.1093/ndt/gfab042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfab042</ArticleId><ArticleId IdType="pmc">PMC7928708</ArticleId><ArticleId IdType="pubmed">33576823</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivero J., Merino-L&#xf3;pez M., Olmedo R., Garrido-Roldan R., Moguel B., Rojas G., et al. Association between postmortem kidney biopsy findings and acute kidney injury from patients with SARS-CoV-2 (COVID-19) Clin J Am Soc Nephrol. 2021;16:685&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8259494</ArticleId><ArticleId IdType="pubmed">33782033</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun F., Huber T.B., Puelles V.G. Proximal tubular dysfunction in patients with COVID-19: what have we learnt so far? Kidney Int. 2020 doi: 10.1016/j.kint.2020.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.09.002</ArticleId><ArticleId IdType="pmc">PMC7480737</ArticleId><ArticleId IdType="pubmed">32916178</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebedev L., Sapojnikov M., Wechsler A., Varadi-Levi R., Zamir D., Tobar A., et al. Minimal change disease following the Pfizer-BioNTech COVID-19&#xa0;vaccine. Am J Kidney Dis. 2021 doi: 10.1053/j.ajkd.2021.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2021.03.010</ArticleId><ArticleId IdType="pmc">PMC8028833</ArticleId><ArticleId IdType="pubmed">33839200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kervella D., Jacquemont L., Chapelet-Debout A., Deltombe C., Ville S. Minimal change disease relapse following SARS-CoV-2&#xa0;mRNA vaccine. Kidney Int. 2021 doi: 10.1016/j.kint.2021.04.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.04.033</ArticleId><ArticleId IdType="pmc">PMC8098029</ArticleId><ArticleId IdType="pubmed">33964312</ArticleId></ArticleIdList></Reference><Reference><Citation>Maas R.J., Gianotten S., van der Meijden W.A.G. An additional case of minimal change disease following the Pfizer-BioNTech COVID-19&#xa0;vaccine. Am J Kidney Dis. 2021 doi: 10.1053/j.ajkd.2021.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2021.05.003</ArticleId><ArticleId IdType="pmc">PMC8116318</ArticleId><ArticleId IdType="pubmed">33992727</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agati V.D., Kudose S., Bomback A.S., Adamidis A., Tartini A. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19&#xa0;vaccine. Kidney Int. 2021 doi: 10.1016/j.kint.2021.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.04.035</ArticleId><ArticleId IdType="pmc">PMC8123374</ArticleId><ArticleId IdType="pubmed">34000278</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaba H., Wada T., Fukagawa M. Relapse of minimal change disease following the Pfizer-BioNTech COVID-19&#xa0;vaccine. Am J Kidney Dis. 2021 doi: 10.1053/j.ajkd.2021.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2021.05.006</ArticleId><ArticleId IdType="pmc">PMC8137360</ArticleId><ArticleId IdType="pubmed">34023417</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzworth A., Couchot P., Cruz-Knight W., Brucculeri M. Minimal change disease following the Moderna mRNA-1273&#xa0;SARS-CoV-2&#xa0;vaccine. Am J Kidney Dis. 2021 doi: 10.1016/j.kint.2021.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.007</ArticleId><ArticleId IdType="pmc">PMC8149162</ArticleId><ArticleId IdType="pubmed">34048824</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwotzer N., Kissling S., Fakhouri F. Letter regarding &#x201c;Minimal change disease relapse following SARS-CoV-2&#xa0;mRNA vaccine.&#x201d;. Am J Kidney Dis. 2021 doi: 10.1016/j.kint.2021.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.006</ArticleId><ArticleId IdType="pmc">PMC8156905</ArticleId><ArticleId IdType="pubmed">34052236</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin P., Bassand X., Benotmane I., Bouvier N. Gross hematuria following SARS-CoV-2&#xa0;vaccination in patients with IgA nephropathy. Am J Kidney Dis. 2021 doi: 10.1016/j.kint.2021.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.022</ArticleId><ArticleId IdType="pmc">PMC8166778</ArticleId><ArticleId IdType="pubmed">34087252</ArticleId></ArticleIdList></Reference><Reference><Citation>Negrea L., Rovin B.H. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus&#xa0;2&#xa0;in 2&#xa0;patients with IgA nephropathy. Kidney Int. 2021;99:1487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987498</ArticleId><ArticleId IdType="pubmed">33771584</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahim S.E.G., Lin J.T., Wang J.C. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2&#xa0;vaccination. Am J Kidney Dis. 2021 doi: 10.1016/j.kint.2021.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.04.024</ArticleId><ArticleId IdType="pmc">PMC8079938</ArticleId><ArticleId IdType="pubmed">33932458</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H.Z., Tan R.Y., Jun Choo J.C., Lim C.C., Tan C.S., Liang Loh A.H., et al. Is COVID-19&#xa0;vaccination unmasking glomerulonephritis? Am J Kidney Dis. 2021 doi: 10.1016/j.kint.2021.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.009</ArticleId><ArticleId IdType="pmc">PMC8141343</ArticleId><ArticleId IdType="pubmed">34033857</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderegg M.A., Liu M., Saganas C., Montani M., Vogt B., Huynh-Do U., et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Am J Kidney Dis. 2021 doi: 10.1016/j.kint.2021.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.016</ArticleId><ArticleId IdType="pmc">PMC8166777</ArticleId><ArticleId IdType="pubmed">34087251</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin M.F., Yildiz A., Oruc A., Sezen M., Dilek K., Gullulu M., et al. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2&#xa0;virus vaccination. Am J Kidney Dis. 2021 doi: 10.1016/j.kint.2021.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.001</ArticleId><ArticleId IdType="pmc">PMC8116315</ArticleId><ArticleId IdType="pubmed">33992674</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekar A., Campbell R., Tabbara J., Rastogi P. Anca glomerulonephritis post Moderna covid-19&#xa0;vaccination. Am J Kidney Dis. 2021 doi: 10.1016/j.kint.2021.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.017</ArticleId><ArticleId IdType="pmc">PMC8166044</ArticleId><ArticleId IdType="pubmed">34081948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A., Anders H.J., Fernandez-Ju&#xe1;rez G.M., Floege J., Goumenos D., Segelmark M., et al. Recommendations for the use of COVID-19&#xa0;vaccines in patients with immune-mediated kidney diseases. Nephrol Dial Transplant. 2021 doi: 10.1093/ndt/gfab064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfab064</ArticleId><ArticleId IdType="pmc">PMC7989374</ArticleId><ArticleId IdType="pubmed">33693778</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>